IL17B and neoplasm: Similarly, IL-17B or IL-17RB silencing in cancer cells or treatment with antibodies targeting IL-17RB reduced proliferation of MDA-MB361 breast cancer cells and MOLM-13 AML cells in vitro and tumor growth in vivo in xenograft models based on these cell lines (28, 38).